Our current study finding is corroborated by previous reports alluding to the chemosensitizing capacity of PIP to other chemotherapeutic agents in estrogen-dependent30,31 and HER2-positive32 breast cancer subtypes. The gene discussed is ERBB2; the disease is breast carcinoma.